Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 8/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5774764 | 0.76 | FAAH (0.60) | PTK2HTR1AFAAHDRD4NPC1 | |
| SCHEMBL5776029 | 0.74 | FAAH (0.46) | PTK2ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL5318658 | 0.73 | NPC1 (0.68) | ALDH1A1HPGDSMN1; SMN2NPC1RAB9A | |
| SCHEMBL3605056 | 0.71 | FAAH (0.74) | FAAH | |
| SCHEMBL12647223 | 0.70 | ALDH1A1 (0.62) | PTK2ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL12522917 | 0.70 | ALDH1A1 (0.62) | PTK2ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL5777529 | 0.70 | ALDH1A1 (0.62) | PTK2ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL354679 | 0.69 | ALDH1A1 (1.00) | PTK2ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL29623278 | 0.69 | ALDH1A1 (1.00) | PTK2ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL25171674 | 0.69 | HDAC4 (0.49) | PTK2ALDH1A1HPGDALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343780-B1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS | SMITHKLINE BEECHAM PLC (GB) | 2006-09-20 | — | — | EP | claimed |
| US-20040077655-A1 | Piperazine derivatives for treatment of bacterial infections | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-04-22 | — | — | US | claimed |
| EP-1343780-B1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS | SMITHKLINE BEECHAM PLC (GB) | 2006-09-20 | — | — | EP | disclosed |
| US-20040077655-A1 | Piperazine derivatives for treatment of bacterial infections | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-04-22 | — | — | US | disclosed |
| EP-1343780-A1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS | SMITHKLINE BEECHAM PLC (GB) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002050061-A1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077655-A1 | Piperazine derivatives for treatment of bacterial infections | MYD88, THPO, PIGO | PTK2 3661/4885ALDH1A1 1678/4885HPGD 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.